From: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
 | Phase 2 | Validation |
---|---|---|
14Â days intention-to-treat | Â | Â |
No. of events/no. of patients at risk | 55/299 | 101/884 |
Lethality rate, % (97.5% CI) | 18.4% (13.6–24.0) | 11.4% (9.1–14.0) |
P value (P0 = 20%) | 0.52 |  < 0.001 |
14Â days modified intention-to-treat | Â | Â |
No. of events/no. of patients at risk | 28/180 | 56/515 |
 Lethality rate, % (95% CI) | 15.6% (10.6–21.7) | 10.9% (8.3–13.9) |
30Â days intention-to-treat | Â | Â |
No. of events/No. of patients at risk | 67/299 | 158/858 |
 Lethality rate, % (97.5% CI) | 22.4% (17.2–28.3) | 18.4% (15.5–21.6) |
 P value (P0 = 35%) |  < 0.001 |  < 0.001 |
 Median time of death, days (IQR) | 8 (4–14) | 11 (4–18) |
30Â days modified intention-to-treat | Â | Â |
No. of events/no. of patients at risk | 36/180 | 99/495 |
 Lethality rate, % (95% CI) | 20.0% (14.4–26.6) | 20.0% (16.6–23.8) |